Clinical-stage biotechnology firm Imunon Inc.

(NASDAQ:IMNN) on Thursday announced an update on its pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 in newly diagnosed advanced ovarian cancer patients.

The company reported site activation and patient enrollment speeds that significantly outpace original forecasts and standard industry benchmarks.

Enrollment Rates Exceed Industry Benchmarks The trial progressed from protocol submission to site activation in roughly six months.

It reached its first randomized patient within two months of approval—one-third of the standard industry benchmark.